Pan-cancer and multi-omics analyses revealed the diagnostic and prognostic value of BAZ2A in liver cancer-Reference-Cited by-同舟云学术

Pan-cancer and multi-omics analyses revealed the diagnostic and prognostic value of BAZ2A in liver cancer

Published:2023-11-14 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Liu Yan¹,Wang Junli¹,Guo Jimin¹,Zhang Qianyi¹,Wang Shuqing²,Hu Fen¹,Wu Jinghua³,Zhao Yating²,Zhang Jinghua³,Yu Yuan¹,Li Yufeng⁴,Zhang Xiaojun⁵

Affiliation:

1. North China University of Science and Technology

2. Hospital of North China University of Science and Technology

3. North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Hospital

4. The Cancer Institute, Tangshan People’s Hospital

5. People's Hospital of Zunhua

Abstract

Abstract BAZ2A, an epigenetic regulatory factor that affects ribosomal RNA transcription, has been shown to be highly expressed in several cancers and promotes tumor cell migration. This study explored the expression and mechanism of BAZ2A in tumorigenesis at the pan-cancer level. The Cancer Genome Atlas, Gene Expression Omnibus databases and TIMER2.0, cBioPortal and other tools were used to analyze the level of expression of BAZ2A in various tumor tissues and to examine the relationship between BAZ2A and survival, prognosis, mutation and immune invasion. In vitro experiments were performed to assess the function of BAZ2A in cancer cells. Using combined transcriptome and proteome analysis, we examined the possible mechanism of BAZ2A in tumors. BAZ2A exhibited high expression levels in multiple tumor tissues and displayed a significant association with cancer patient prognosis. The main type of BAZ2A genetic variation in cancer is gene mutation. Downregulation of BAZ2A inhibited proliferation, migration, and invasion and promoted apoptosis in LM6 liver cancer cells. The mechanism of BAZ2A in cancer development may involve lipid metabolism. These results help expand our understanding of BAZ2A in tumorigenesis and development and suggest BAZ2A may serve as a prognostic and diagnostic factor in several cancers.

Publisher

Research Square Platform LLC

Reference33 articles.

1. BRAY,F.et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.68,394–424;10.3322/caac.21492(2018).

2. SUNG,H.et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71,209–249;10.3322/caac.21660(2021).

3. SIEGEL,R.L., MILLER,K.D., JEMAL,A. Cancer statistics, 2019. CA Cancer J Clin. 69,7–34;10.3322/caac.21551(2019).

4. LI,H.et al. TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.Front Immunol. 12,764 – 749;10.3389/fimmu.2021.764749(2021).

5. DALLE,V.A.et al. Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing. ACS Med Chem Lett. 13,1434–1443;10.1021/acsmedchemlett.2c00173(2022).